An Exploratory Phase 2/3, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB

Trial Profile

An Exploratory Phase 2/3, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary)
  • Indications Proteinuria; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DELIGHT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Mar 2017 Planned End Date changed from 1 May 2018 to 18 May 2018.
    • 08 Mar 2017 Planned primary completion date changed from 1 May 2018 to 18 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top